STOCK TITAN

Sagimet Biosciences (SGMT) SEC Filings

SGMT NASDAQ

Sagimet Biosciences Inc. filings document a clinical-stage biopharmaceutical issuer with Series A common stock listed on the Nasdaq Global Market and emerging growth company status. Recent 8-K reports cover financial results, preliminary financial information, Regulation FD investor presentations, a material underwriting agreement and related capital-structure disclosures, and executive leadership changes.

The company’s proxy materials describe annual meeting voting matters, stockholder procedures, board-related items, and governance proposals. Its disclosures also track use-of-proceeds language, clinical-development updates for FASN inhibitor programs, and public-company reporting matters.

Rhea-AI Summary

Sagimet Biosciences Inc. (SGMT) investment adviser Woodline Partners LP reported beneficial ownership of 3,143,952 shares of Series A common stock, equal to 5.1% of the class. Woodline Partners reported sole voting and dispositive power over those shares and no shared power. The shares are directly held by Woodline Master Fund LP; Woodline said the report is not an admission of beneficial ownership for Section 13 purposes. The percentage is based on 61,591,159 shares outstanding as of August 4, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
ownership
-
Rhea-AI Summary

An amended Schedule 13G concerning Sagimet Biosciences Inc. (SGMT) reports that five reporting persons may each be deemed to beneficially own 5,542,492 Series A common shares, approximately 9.00% of the class. The shares are held directly by Atlas Diversified Master Fund, Ltd. (3,042,492 shares) and Atlas Private Holdings (Cayman) Ltd. (2,500,000 shares). Balyasny Asset Management L.P., BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC and Dmitry Balyasny report sole voting and dispositive power over the shares through the stated management and control relationships. The percentage is based on 61,591,159 shares outstanding as of August 4, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
ownership
-
Rhea-AI Summary

Sagimet Biosciences Inc. (SGMT) is the issuer in a Schedule 13G reporting that SilverArc Capital Management, LLC, an investment adviser, and its sole member Devesh Gandhi are each beneficial owners of 3,745,990 Class A common shares, or 6.1%. The report identifies September 30, 2026, as the event date. Both report shared voting and dispositive power over the same shares; these are overlapping attributions, not separate holdings. SilverArc says its clients have the right to receive and direct dividends and sale proceeds. The reported percentage is based on 61,591,159 common shares outstanding, according to the issuer's Form 10-Q dated August 11, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
ownership
Rhea-AI Summary

Sagimet Biosciences Inc. reported a $19.149 million net loss for the third quarter of 2026, compared with $12.908 million a year earlier. Research and development expense was $16.340 million, versus $9.730 million; general and administrative expense was $5.227 million, versus $4.604 million. Cash, cash equivalents and marketable securities totaled $275.822 million at September 30, 2026. A company presentation cited approximately $356 million in pro forma cash as of that date, including a $115 million equity financing completed in October, and said it was expected to fund operations through mid-2029.

Sagimet said it initiated the pivotal U.S. AURORA Phase 3 acne trial, with the first patient dosed in October 2026 and topline results expected in the second half of 2027. The trial is expected to enroll approximately 800 U.S. patients, including 450 adolescents; a Phase 2 trial of TVB-3567 is planned before the end of 2026. In China, license partner Ascletis reported that denifanstat met all primary and secondary endpoints in a Phase 3 trial. Sagimet said further MASH development depends on securing non-dilutive funding.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.21%
Tags
current report
-
Rhea-AI Summary

Sagimet Biosciences Inc. reported third-quarter 2026 research and development expense of $16.34 million, up 68% from $9.73 million a year earlier, primarily reflecting clinical development and manufacturing activity. Net loss was $19.149 million versus $12.908 million; nine-month net loss was $43.752 million versus $41.470 million. Net cash used in operating activities for nine months was $31.8 million, compared with $33.8 million a year earlier.

Cash, cash equivalents and marketable securities totaled $275.8 million at September 30, 2026. On October 1, Sagimet completed an offering of 8,750,010 Series A shares at $10.00 each and pre-funded warrants to purchase 2,750,010 shares at $9.9999 each, for approximately $115.0 million in gross proceeds and estimated net proceeds of approximately $107.5 million. Sagimet expects these resources to fund operating expenses for at least 12 months from issuance of the financial statements.

The company reported that the first patient had been dosed in its U.S. Phase 3 AURORA acne trial. In China, license partner Ascletis reported full 52-week open-label extension results, including a 56.7% treatment-success rate and a 71.8% mean reduction in total lesion count among 240 patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.21%
Tags
quarterly report
-
Rhea-AI Summary

Sagimet Biosciences Inc. updated its investor presentation, describing denifanstat’s clinical progress in acne and metabolic dysfunction-associated steatohepatitis (MASH), and development plans for TVB-3567. In the China Phase 3 acne trial conducted by license partner Ascletis, denifanstat met all primary and secondary endpoints: IGA treatment success was 33.2% versus 14.6% with placebo, and total lesion counts changed by -57.4% versus -35.4%. Ascletis announced that China’s NMPA accepted the acne NDA for review in December 2025.

In the U.S., the first patient was dosed in the AURORA Phase 3 acne trial in October 2026; it plans to enroll 800 patients, including 450 aged 12–17, with topline results expected in the second half of 2027. For TVB-3567, the SAD/MAD and food-effect parts of Phase 1 are complete, Phase 2 doses have been identified, and Phase 2 is anticipated to begin before the end of 2026. Denifanstat’s Phase 2b MASH trial met both primary endpoints with a significant reduction in fibrosis; further MASH development is conditional on securing non-dilutive funding.

Sagimet completed a $115M underwritten Series A common stock offering in September 2026. The company says its cash, cash equivalents and marketable securities, together with the offering proceeds, are expected to fund current operations through mid-2029, including the U.S. acne Phase 3 readout and NDA submission.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.40%
Tags
current report
Rhea-AI Summary

Sagimet Biosciences Inc. (SGMT) is the issuer in an ownership report by Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson and Michael Kramarz covering its Series A common stock. The filers report aggregate beneficial ownership of 5,507,752 shares, or 7.6%, comprising 2,757,742 common shares and 2,750,010 shares they may acquire through pre-funded warrants. The warrants are subject to a 9.99% beneficial ownership limitation. The reported 7.6% is based on 69,965,450 shares issued and outstanding as of September 30, 2026, plus the 2,750,010 shares the filers may acquire upon warrant exercise. Commodore Capital LP is the investment manager to Commodore Capital Master LP; Atkinson and Kramarz are its managing partners and exercise investment discretion over the securities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
ownership
-
Rhea-AI Summary

Sagimet Biosciences Inc. agreed to sell 8,750,010 shares of Series A common stock at $10.00 per share and pre-funded warrants to purchase up to 2,750,010 shares at an offering price of $9.9999 per share issuable upon exercise. The offering is expected to close October 1, 2026, subject to customary closing conditions; the company expects $107.5 million in net proceeds after underwriting discounts and commissions.

The company plans to use the proceeds together with existing cash, cash equivalents and marketable securities for a Phase 3 denifanstat acne trial, denifanstat pre-launch activities, TVB-3567 through Phase 2 topline results, its topical FASN inhibitor program through IND submission, and general corporate purposes. The warrants are immediately exercisable at $0.0001 per share. Exercise is subject to a beneficial ownership limit of 4.99%, or 9.99% at a purchaser’s election; holders may adjust the limit up to 19.99% with at least 61 days’ prior notice.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.16%
Tags
current report
-
Rhea-AI Summary

Sagimet Biosciences Inc. (SGMT) is offering 8,750,010 shares of Series A common stock and pre-funded warrants to purchase 2,750,010 shares. Prices are $10.00 per share and $9.9999 per warrant; warrants are immediately exercisable at $0.0001 per share. The aggregate offering price is $114,999,925; estimated net proceeds are approximately $107.5 million, excluding proceeds from warrant exercises. Sagimet intends to use proceeds and existing cash for denifanstat’s planned Phase 3 acne trial and pre-launch work, TVB-3567 through Phase 2 topline results, its topical FASN inhibitor program through IND submission, and general corporate purposes. Immediate dilution to new investors is calculated at $4.87 per share.

Sagimet reported 52-week results from a China open-label extension involving 240 acne patients: overall treatment success was 56.7%, and mean total lesion count change from baseline was -71.8%. It plans a U.S. registrational Phase 3 acne trial in the second half of 2026; a TVB-3567 Phase 2 trial is anticipated before year-end 2026, subject to regulatory consultation and Phase 1 results.

The pre-funded warrants have no established public trading market. Sagimet says it will undertake no further MASH clinical development until it obtains non-dilutive financing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.16%
Tags
prospectus
Rhea-AI Summary

Sagimet Biosciences Inc. (SGMT) reported positive 52-week results from ASC40-304, a Phase 3 open-label denifanstat extension trial in moderate to severe acne conducted in China by license partner Ascletis BioScience Co. Ltd. Among 240 patients, treatment success was 56.7%; mean changes from ASC40-303 baseline were -71.8% in total lesion count, -76.9% in inflammatory lesion count and -66.9% in non-inflammatory lesion count. Success required a 2-point IGA reduction from baseline to 0 or 1.

All 240 extension patients received denifanstat 50 mg once daily for up to 40 weeks; the 116 originally assigned denifanstat had up to 52 weeks of total exposure. Effective September 30, 2026, Sagimet suspended and terminated its ATM prospectus supplement. It will make no Series A common stock sales under the Sales Agreement unless and until a new prospectus, prospectus supplement or registration statement is filed; the agreement remains in effect. The company said its cash position was expected to fund current operations through 2028 and through readout of its U.S. Phase 3 acne trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.89%
Tags
current report

FAQ

How many Sagimet Biosciences (SGMT) SEC filings are available on StockTitan?

StockTitan tracks 77 SEC filings for Sagimet Biosciences (SGMT), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Sagimet Biosciences (SGMT)?

The most recent SEC filing for Sagimet Biosciences (SGMT) was filed on November 16, 2026.